Wednesday, January 20, 2021
Home Covid-19 Results from Phase 3 of Moderna's vaccine trial show an efficacy of...

Results from Phase 3 of Moderna’s vaccine trial show an efficacy of 94.1%


A peer-reviewed article published in The #New #England #Journal of #Medicine provides data from the highly anticipated COVE study, which evaluated mRNA-1273, a candidate vaccine against COVID-19 manufactured by #Moderna, #Inc (REUTERS)

The investigational vaccine known as mRNA-1273 was 94.1% effective in preventing symptomatic coronavirus disease (COVID-19), based on preliminary results of a #Phase 3 clinical trial published in the #New #England #Journal of #Medicine. The vaccine also demonstrated efficacy in preventing severe COVID-19. The researchers did not identify safety concerns or evidence of vaccine-associated improved respiratory disease.

The vaccine was jointly developed by #Moderna, #Inc., a biotechnology company based in #Cambridge, #Massachusetts, and the #National #Institute of #Allergy and #Infectious #Diseases (NIAID), part of the #National #Institutes of #Health. #Moderna and NIAID previously shared the initial results of the COVE trial. #On #December 18, 2020, the FDA issued an emergency use authorization allowing #Moderna to make available the vaccine for the prevention of COVID-19 in adults in the #United #States.

- Advertisement -

#Essay was led by principal investigators #Lindsey R. #Baden, del #Brigham and #Women’s #Hospital en #Boston, #Hana M. #El-Sahly, from #Baylor #College of #Medicine in #Houston, and #Brandon #Essink, de #Meridian #Clinical #Research. The test was implemented under the #Operation #Warp #Speed ​​program of the #United #States government and received the support of NIAID and the #Advanced #Biomedical #Research and #Development #Authority of the #Office of the #Assistant #Secretary for #Preparedness and #Response of the #Department of #Health and #Human #Services of the #North #American country.

The incidence of symptomatic COVID-19 was 94.1% lower in participants who received mRNA-1273 compared to those who received placebo (EFE)
The incidence of symptomatic COVID-19 was 94.1% lower in participants who received mRNA-1273 compared to those who received placebo (EFE)

The trial began on #July 27, 2020 and enrolled 30,420 adult volunteers at clinical research sites throughout the #United #States. #Volunteers were randomly assigned 1: 1 to receive two 100-microgram (mcg) doses of the investigational vaccine or two injections of placebo saline 28 days apart. The middle #Ages of the volunteers is 51 years. #Approximately 47% are women, 25% are 65 or older, and 17% are under 65 and medical conditions put them at higher risk for severe COVID-19. #Approximately 79% of the participants are #White, 10% are #Black or #African #American, 5% are #Asian, 0.8% are #American #Indian or #Alaska #Native, 0.2% are #Native #Hawaiian or other islands in the #Pacific, 2% are multiracial and 21% (of any race) are #Hispanic or #Latino.

#From the start of the trial to #November 25, 2020, researchers recorded 196 cases of symptomatic COVID-19 what happened between the participants at least 14 days after receiving your second injection. #One hundred and eighty-five cases (30 of which were classified as severe COVID-19) occurred in the placebo group and 11 cases (0 of which were classified as severe COVID-19) occurred in the group that received mRNA-1273. The incidence of symptomatic COVID-19 was 94.1% lower in participants who received mRNA-1273 compared to those who received placebo.

The researchers observed 236 cases of symptomatic COVID-19 among the participants at least 14 days after receiving their first injection, with 225 cases in the placebo group and 11 cases in the group that received mRNA-1273. The efficacy of the vaccine was 95.2% for this secondary analysis.

There were no safety concerns related to vaccination, according to the authors. The local reactions they went to the vaccine generally mild. #Approximately 50% of the participants who received mRNA-1273 experienced moderate to severe side effects such as fatigue, muscle aches, joint pain, and headache after the second dose, it resolved in most volunteers within two days.

Although mRNA-1273 is very effective in preventing symptomatic COVID-19, there is not yet enough data available to draw conclusions about whether the vaccine can affect the transmission of SARS-CoV-2 (EFE)
#Although mRNA-1273 is very effective in preventing symptomatic COVID-19, there is not yet enough data available to draw conclusions about whether the vaccine can affect the transmission of SARS-CoV-2 (EFE)
- Advertisement -

#Researchers they also did not see evidence of vaccine-associated increased respiratory illness among those who received mRNA-1273. #This rare complication was seen in people vaccinated with a fully inactivated respiratory syncytial virus (RSV) vaccine in the 1960s, before the ability to define protein structures and accurately measure immune responses existed. The same #It can occur when a vaccine induces an immune response that is not strong enough to protect against infection.

#Although mRNA-1273 is very effective in preventing symptomatic COVID-19, There is not yet enough data available to draw conclusions about whether the vaccine can affect the transmission of SARS-CoV-2. #Preliminary data from the trial suggest that there may be some degree of prevention of asymptomatic infection after a single dose. #Additional analyzes of the incidence of asymptomatic infection and viral shedding after infection are under way to understand the impact of the vaccine on infectivity.

The authors concluded by discussing the unprecedented efficiency of candidate vaccine development and noted that “this process demonstrates what is possible in the context of motivated collaboration between key sectors of society, including academia, government, industry, regulators and the community at large ”.

I KEEP READING:

They prove that #Moderna’s vaccine is effective in older adults

The differences between the FDA approval process for the #Pfizer and #Moderna vaccines and the ANMAT regarding #Sputnik V

- Advertisement -

#Kamala #Harris, vice president-elect of the #United #States, received #Moderna’s vaccine against the coronavirus





[ source link ]
https://www.infobae.com/america/ciencia-america/2020/12/30/los-resultados-de-la-fase-3-del-ensayo-de-la-vacuna-de-moderna-muestran-una-eficacia-del-941/

##Results ##Phase ##Modernas #vaccine #trial #show #efficacy

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments